2001 MARKET STREET, PHILADELPHIA, PA
Context Therapeutics Enters $75 Million Sales Agreement with Leerink Partners
Other Events
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Shareholder votes
Investor Presentation
Annual Report to Security Holders
Doses First Patient in Phase 1 Clinical Trial of CT-95
Q2
Q1
FY 2024
Q3
FY 2023
Prospectus filed pursuant to Rule 424(b)(5)
Registration Statement for Securities to be Offered to Employees
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Prospectus filed pursuant to Rule 424(b)(3)
Additional Proxy Materials
Definitive Proxy Statement
PRE 14A
Statement of Changes in Beneficial Ownership